CSL N Stock Overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CSL Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3,635.42 |
| 52 Week High | AU$3,635.42 |
| 52 Week Low | AU$3,635.42 |
| Beta | 0.20 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -15.46% |
| 5 Year Change | n/a |
| Change since IPO | 27.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| CSL N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how CSL N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how CSL N performed against the MX Market.
Price Volatility
| CSL N volatility | |
|---|---|
| CSL N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: CSL N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CSL N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1916 | 30,000 | Paul McKenzie | www.csl.com.au |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.
CSL Limited Fundamentals Summary
| CSL N fundamental statistics | |
|---|---|
| Market cap | Mex$1.73t |
| Earnings (TTM) | Mex$38.12b |
| Revenue (TTM) | Mex$210.68b |
45.3x
P/E Ratio8.2x
P/S RatioIs CSL N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSL N income statement (TTM) | |
|---|---|
| Revenue | US$11.70b |
| Cost of Revenue | US$5.56b |
| Gross Profit | US$6.15b |
| Other Expenses | US$4.03b |
| Earnings | US$2.12b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.39 |
| Gross Margin | 52.52% |
| Net Profit Margin | 18.09% |
| Debt/Equity Ratio | 59.7% |
How did CSL N perform over the long term?
See historical performance and comparison